Podcasts Science Meet The Microbiologist 081: Developing infectious disease diagnostics with Melissa Miller

081: Developing infectious disease diagnostics with Melissa Miller

Published: April 26, 2018, 9:34 p.m.

b'

How are new diseases detected in a clinical microbiology lab? Melissa Miller talks about the time it takes to develop a test for a new disease (hint: it\\u2019s getting shorter). She also shares her definition of \\u2018point-of-care\\u2019 diagnostics and explains the major trends for clinical microbiology labs.

Host: Julie Wolf\\xa0

Subscribe (free) on iPhone, Android, RSS, or by email. You can also\\xa0listen on your mobile device with the ASM Podcast app.

Julie\'s biggest takeaways:

  • Antibiograms are vital to understand the resistance characteristics of locally circulating disease strains. These help make empirical decisions for antibiotic therapy regimens before the susceptibility test results are available.

  • New diseases require new diagnostic tests. How to determine how well new tests work once they\\u2019re developed? Clinical microbiologists look to the sensitivity (how well does a test detect if a patient has a disease) and specificity (how often is the test negative if the patients doesn\\u2019t have it) of the test. Having access to positive controls (that is, samples from a patient known to have the disease) can prove difficult in some settings, such as in North Carolina, where no Zika patients were admitted while the Zika virus test was being developed.

  • When the HIV epidemic was beginning, it took several years after the HIV virus was identified to sequence its genome and use this for molecular testing. In 2002-2003, it took just over a month to get the SARS genome sequence for use in developing assays. It\\u2019s even quicker today; within a week, we can have sequences from viruses around the world.

  • Defining \\u2018point-of-care\\u2019 testing took an entire hour at a recent American Academy of Microbiology colloquium! Melissa\\u2019s take: It\\u2019s a test that can be done at or near to where the patient is.

  • Point-of-care tests are exciting but can also pose challenges. A recent example is false-positive pertussis tests that were shown to be due to pertussis vaccine being administered nearby. Ensuring the tests are used safely and accurately will best serve healthcare workers and patients alike.

  • Molecular diagnostics have two trends: one trend simplifies existing technologies into point-of-care tests. The other trend adds complexity, by applying next-generation sequencing techniques in a reproducible manner.

Featured Quotes (in order of appearance):

\\u201cLaboratorians are often in the basement or in a setting where they aren\\u2019t visible to the healthcare team, but they\\u2019re very vital to taking care of the patient.\\u201d

\\xa0

\\u201cWhen you\\u2019re using laboratory-developed tests, the way it works in one laboratory may be very different from how it works in another laboratory.\\u201d

\\xa0

\\u201cThe ultimate goal [of point-of-care testing] is to get a result that\\u2019s actionable. We don\\u2019t need to do tests that aren\\u2019t going to result in a clinically actionable decision.\\u201d

\\xa0

\\u201cIn many ways, the technology is ahead of where our quality assurance protocols are.\\u201d

\\xa0

\\u201cI think it\\u2019s going to be very important in going ahead that we continue to have laboratorians involved in developing these point-of-care programs and consulting to these sites, helping to make sure that there are policies and procedures that ensure quality results for their patients.\\u201d

\\xa0

\\u201cIt\\u2019s one thing to do it in a research setting; we\\u2019ve collaborated with a number of folks using next generation sequencing. But to then move it to the clinical lab and have it be reproducible and have the quality at the level you need for a clinical lab is a completely different challenge.\\u201d

Links for this episode

Send your stories about our guests and/or your comments to\\xa0jwolf@asmusa.org.

\\xa0

'